Skip to content
GinjerNews

The GLP-1 boom has a dark side — even if serious complications are rare

By Ariana Eunjung Cha, Daniel Wu

Lawsuits raise a difficult question: When millions of people are taking new drugs, how much evidence of a devastating risk is enough to require a warning?

This story was published by The Washington Post. Read the full article on their site.

Read the full story at washingtonpost.com(opens in a new tab)

More News